GlassScriptPhysician profile
Rahim Kassamali
NPI 1932162641
$505.70
in general payments reported to CMS, 2019-2025
13 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $36.95 · 2021: $15.40 · 2023: $12.69 · 2024: $125 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.06 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $135.85 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $63.75 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.02 | 2025 | |
| Fresenius USA Marketing, INC. | $51.78 | 2019-2024 | Velphoro |
| Amgen INC. | $42.48 | 2019 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $23.94 | 2025 | Farxiga |
| Baxter Healthcare | $23.27 | 2024 | Renal - Pd |
| Apellis Pharmaceuticals, INC. | $21.35 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.78 | 2025 | |
| Tris Pharma INC | $16.74 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.31 | 2025 | Terlivaz |
| Mallinckrodt Enterprises LLC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahim Kassamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.